A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases
← catalyst calendarNCT07782450 · readout in 1,642 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With Syneos.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
54estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-24
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-16 | estimated | When the study began enrolling |
| Primary completion | 2031-02-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-02-22 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- Idiopathic Inflammatory Myositis
- Systemic Sclerosis
Intervention
- Drug: PF-08154225
Primary outcomes
what the primary-completion date above is the date OFIncidence and severity of Treatment Emergent Adverse Event (AE) including protocol specified adverse event of special interest(AESI)
measured From first dose through End of Study (up to Week 16 in Part 1a, Week 24 in Part 1b and Week 52 in Part2)
Dose Limiting Toxicity (DLT)
measured During the DLT observation period (up to 22 days after the last dose)
Frequencies of abnormal safety laboratory tests, vital signs, ECGs.
measured From first dose of study intervention through End of Study (up to Week 16 in Part 1a, Week 24 in Part 1b and Week 52 in Part 2)
Related
PFE · their whole pipeline · Systemic Lupus Erythematosus readouts · Congress trades in PFE · Executive-branch trades in PFE
PFE's other studiesmost recently updated first
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Phase 1 · Recruiting
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments Phase 3 · Recruiting
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects Phase 3 · Recruiting
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant Phase 3 · Recruiting
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Phase 3 · Recruiting
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed